CytoSorbents Corporation is a development stage critical care focused company using blood purification to treat life-threatening illnesses. The technology is based upon biocompatible, highly porous polymer sorbent beads that are capable of extracting unwanted substances, such as drugs, dangerous chemicals, toxins, cytokines, free hemoglobin, and antibodies, from blood and other bodily fluids. Its CE Mark enables CytoSorb to be sold throughout the entire European Union. In addition to the sepsis indication, the Company continues to foster research in other critical care illnesses where CytoSorb could be used, such as ARDS, trauma, severe burn injury, acute pancreatitis, and in other acute conditions that may benefit by the reduction of cytokines in the bloodstream.
|Headquarters||Suite K, 7 Deer Park Drive|
MONMOUTH JUNCTION, NJ, United States 08852
|Chairman of the Board||Al Kraus|
|President, Chief Executive Officer, Director||Phillip Chan|
|Chief Financial Officer||Kathleen Bloch|
|Chief Operating Officer||Vincent Capponi|
|Chief Medical Officer||Robert Bartlett|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P Capital IQ, INK and Argus.
|Shares Out.||245.1M||Book Value||$0.01|
|Cytosorbents Corp does not pay a dividend.||P/E||--|
|P/Cash Flow (TTM)||--|
*GAAP = prior to non-GAAP analyst adjusted earnings.